Dana Investment Advisors Inc. Has $7.51 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN

Dana Investment Advisors Inc. lessened its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 11.7% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 331,656 shares of the company’s stock after selling 43,983 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Elanco Animal Health were worth $7,505,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of ELAN. Independent Advisor Alliance increased its position in Elanco Animal Health by 364.5% during the third quarter. Independent Advisor Alliance now owns 98,025 shares of the company’s stock worth $1,974,000 after acquiring an additional 76,920 shares during the period. State of Michigan Retirement System bought a new position in Elanco Animal Health during the third quarter worth about $2,383,000. Amalgamated Bank increased its position in Elanco Animal Health by 793.7% during the third quarter. Amalgamated Bank now owns 226,580 shares of the company’s stock worth $4,563,000 after acquiring an additional 201,226 shares during the period. Teachers Retirement System of The State of Kentucky bought a new position in Elanco Animal Health during the third quarter worth about $2,215,000. Finally, Royce & Associates LP increased its position in Elanco Animal Health by 21.3% during the third quarter. Royce & Associates LP now owns 602,564 shares of the company’s stock worth $12,136,000 after acquiring an additional 105,632 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

ELAN stock opened at $19.85 on Friday. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 12 month low of $12.40 and a 12 month high of $27.72. The firm has a market cap of $9.92 billion, a P/E ratio of -39.71, a P/E/G ratio of 2.12 and a beta of 1.69. The company’s 50-day moving average price is $23.31 and its two-hundred day moving average price is $23.33.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same period last year, the firm earned $0.37 EPS. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, analysts anticipate that Elanco Animal Health Incorporated will post 1.1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ELAN has been the topic of a number of recent research reports. Citigroup raised their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. KeyCorp raised their price target on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Leerink Partners raised their price target on shares of Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Weiss Ratings lowered shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $28.20.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.